Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
Five patients who are on treatment of imatinib and deriving clinical benefit after
CAMN107DBR01 study termination and written informed consent obtained will enter the trial,
all five patients will receive Glivec (8oomg per day) treatment until tumor progression [by
RECIST guidelines, version 1.0], unacceptable toxicity, death or withdrawal of consent.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Jie Zhong, M.D.
Ruijin Hospital of Shanghai Jiaotong University
United States: Food and Drug Administration